Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol

BACKGROUND: Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC). However, patients’ selection thorough the identification of predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottaiano, Alessandro, Scala, Stefania, Normanno, Nicola, Napolitano, Maria, Capozzi, Monica, Rachiglio, Anna Maria, Roma, Cristin, Trotta, Anna Maria, D’Alterio, Crescenzo, Portella, Luigi, Romano, Carmela, Cassata, Antonino, Casaretti, Rossana, Silvestro, Lucrezia, Nappi, Anna, Tafuto, Salvatore, Avallone, Antonio, De Stefano, Alfonso, Tamburini, Mario, Picone, Carmine, Petrillo, Antonella, Izzo, Francesco, Palaia, Raffaele, Albino, Vittorio, Amore, Alfonso, Belli, Andrea, Pace, Ugo, Di Marzo, Massimiliano, Chiodini, Paolo, Botti, Gerardo, De Feo, Gianfranco, Delrio, Paolo, Nasti, Guglielmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734266/
https://www.ncbi.nlm.nih.gov/pubmed/31500586
http://dx.doi.org/10.1186/s12885-019-6109-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734266/
https://www.ncbi.nlm.nih.gov/pubmed/31500586
http://dx.doi.org/10.1186/s12885-019-6109-z

Ejemplares similares